da Silva T L, Pianca T G, Roman T, Hutz M H, Faraone S V, Schmitz M, Rohde L A
ADHD Outpatient Clinic, Child and Adolescent Psychiatric Division, Hospital de Clínicas de Porto Alegre, Federal University of Rio Grande do Sul, Rio Grande do Sul, Brazil.
J Neural Transm (Vienna). 2008;115(2):341-5. doi: 10.1007/s00702-007-0835-0. Epub 2008 Jan 16.
An association between ADRA2A -1291 C > G polymorphism and response to methylphenidate in inattentive symptoms was previously suggested in children with ADHD. No investigation specifically assessed this association in ADHD-inattentive type (ADHD-I). In this naturalistic pharmacogenetic study, 59 subjects with ADHD-I from a non-referred sample were treated with short-acting methylphenidate and genotyped for ADRA2A -1291 C > G polymorphism. The primary outcome measure was the inattentive subscale of the SNAP-IV applied by a child psychiatrist blinded to genotype at baseline and first month of treatment. Children and adolescents with the G allele showed significantly lower inattentive scores with MPH treatment at the first month of treatment than subjects without the G allele (n = 59; F = 6.14; p = 0.016). We extended to ADHD-I previous findings suggesting the influence of the G allele at the ADRA2A -1291 C > G polymorphism on the improvement of inattentive symptoms with methylphenidate in children with all ADHD subtypes.
先前有研究表明，在患有注意力缺陷多动障碍（ADHD）的儿童中，ADRA2A基因-1291位点C＞G多态性与哌甲酯对注意力不集中症状的反应之间存在关联。但尚无研究专门评估这种关联在注意力不集中型ADHD（ADHD-I）中的情况。在这项自然主义的药物遗传学研究中，对59名来自非转诊样本的ADHD-I受试者给予短效哌甲酯治疗，并对其ADRA2A基因-1291位点C＞G多态性进行基因分型。主要结局指标是由一名对基因型不知情的儿童精神科医生在基线和治疗第一个月应用的SNAP-IV注意力不集中分量表。携带G等位基因的儿童和青少年在治疗第一个月接受MPH治疗时，注意力不集中得分显著低于未携带G等位基因的受试者（n = 59；F = 6.14；p = 0.016）。我们将先前的研究结果扩展至ADHD-I，这些结果表明ADRA2A基因-1291位点C＞G多态性中的G等位基因对所有ADHD亚型儿童使用哌甲酯改善注意力不集中症状有影响。
